培美曲塞治疗复发性卵巢癌的疗效观察

Effect of different treatment regimens on recurrent ovarian cancer

摘要:

目的评估培美曲塞治疗复发性卵巢癌的临床效果。方法选取2013 年1 月-2014 年12 月于南通大学附属医院接受治疗的90 例复发性卵巢癌患者作为研究对象，依据随机数字表方法将其分为对照组（n =40）与观察组（n =50）两组，对照组给予紫杉醇联合伊立替康治疗，观察组则应用培美曲塞治疗方案，对比观察两组患者的临床疗效及腹水控制率。结果观察组总有效率66.0%、腹水控制率82.0%，对照组总有效率35.0%、腹水控制率47.5%，组间比较，差异有统计学意义（p <0.05）；两组不良反应发生率分别为38.0%和42.5%，组间比较，差异无统计学意义（p >0.05）；两组治疗后糖类抗原125、人肿瘤坏死因子α、可溶性白细胞介素2 受体及人附睾蛋白4 指标比较，差异有统计学意义（p<0.05） 。结论在复发性卵巢癌患者的临床治疗中，用培美曲塞方案疗效好、安全性高，值得推广。

Abstract:

Objective To evaluate the clinical effect of Pemetrexed in the treatment of recurrent ovarian cancer. Methods Ninety cases of recurrent ovarian cancer patients, who were treated in the Affiliated Hospital of Nantong University from January 2013 to December 2014, were selected as the research objects and randomly divided into control group (40 cases) and observation group (50 cases). The control group was given Paclitaxel combined with Irinotecan therapy, and the observation group received Pemetrexed therapy. The clinical therapeutic effect and ascites control rate were compared between the two groups. Results In the observation group, the total effective rate was 66.0%, the ascites control rate was 82.0%; in the control group,the total effective rate was 35.0%, the ascites control rate was 47.5%, the differences between the two groups were statistically significant (p < 0.05). The incidence of adverse reactions was 38.0% in the observation group and 42.5% in the control group, there was no statistical difference between the two groups (p > 0.05). There were statistical differences in post-treatment levels of CA125, TNF-α, SIL-2r and HE4 between the two groups (p < 0.05). Conclusions In clinical treatment of recurrent ovarian cancer, Pemetrexed has good curative effect and high safety. It is worthy of promotion.